VHIO can and will only deliver on its goal of accelerating the pace in advancing personalized and targeted therapies against cancer thanks to the public funding it receives, as well as through the generous support from private institutions, companies and individuals. Furthermore, and as a direct reflection of VHIO's research of excellence, VHIO continues to secure essential funding through several International and National Competitive Grants.
Only with such continued support will the clock continue to tick in our favor - against cancer. VHIO would therefore like to express its immense gratitude to its following supporters, funding entities and agencies:
As a reflection of VHIO's expertise in preclinical, translational and clinical research in oncology, it participated in the following Consortia of excellence in 2015:
Cancer Core Europe is a unique partnership aimed at addressing the cancer care-cancer research continuum. Launched in the Autumn of 2014, this working consortium represents a critical mass of activity for the successful integration of all cancer care information, clinical research and outcome research, led by the six founding partners and European comprehensive cancer centers of excellence: the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), Cambridge Cancer Centre (Cambridge, UK), Karolinska Institute (Stockholm, Sweden), Netherlands Cancer Institute - NKI (Amsterdam, The Netherlands), National Center for Tumor Diseases - DKFZ-NCT (Heidelberg, Germany), and VHIO. The Cancer Core Europe's pooling and exchange of expertise, research findings, common platforms and processes, will empower researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients. Bookmark and visit VHIO's website forthcoming project updates: www.vhio.net.
COLTHERES - Colon Therapy Research Consortium partners European clinical research centers as well as translational researchers who have received core funding from the European Commission's 7th Framework Programme of Research and Development to define and perform biomarker driven clinical trials to improve cancer therapy outcomes. Launched in 2011, this 4-year programme uses comprehensively molecularlyannotated colon cancers as a 'test-bed' to define specific biomarkers of response or resistance to signalling pathway agents. www.coltheres.eu
Aimed at improved outcomes for cancer patients and reduced mortality across Europe through prevention, early detection and improved treatments, EurocanPlatform, founded in 2011, is funded by the European Commission's 7th Framework Programme and comprises 28 European leading cancer Institutions and organisations working together in a unique collaboration. The centers share infrastructures and collaborate on projects to help advance cancer research and treatment. www.eurocanplatform.eu
The EuroPDX Consortium – Translating Knowledge in Oncology, was launched in 2013 with the common goal of creating a network of clinically relevant models of human cancer, and in particular patient-derived xenograft (PDX) models. Connecting 14 cancer centers across 9 European countries that are developing PDX cancer models, this initiative will promote the sharing and exchange of findings on promising therapeutics as well as lead multi-center preclinical studies. EuroPDX will strive to reduce the duplication of efforts in oncology drug development and ultimately improve the quality of life and overall survival of cancer patients. www.europdx.eu.
Announced in 2013, The MErCuRIC Consortium, funded by the European Commission's 7th Framework Programme of Research and Development, incorporates 13 partners in eight different European countries to lead and pioneer a multicentre phase Ib/II clinical trial. This study will assess a novel therapeutic strategy aimed at combating metastasis, improving survival and developing new approaches to treat patients with colorectal cancer. www.mercuric.eu
Launched in 2011 (VHIO joined in 2013), supported by the IMI Innovative Medicines Initiative – a Joint Undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), OncoTrack, Methods for systematic next generation oncology biomarker development, is an international consortium of over 80 scientists and constitutes one of Europe's largest collaborative academic-industry efforts aimed at developing and assessing novel approaches for the identification of new markers for colon cancer. www.oncotrack.eu.
Launched in 2015, MedBioinformatics is a project supported by Horizon 2020’s European Union funding for Research and Innovation. Through the development of integrative bioinformatics tools and software applications useful and autonomously usable by translational scientists and clinical practitioners for analysing the huge amount of data and knowledge generated in healthcare and biomedical research, the project will ultimately facilitate translational research and precision medicine.
Incorporating 13 groups from nine renowned research entities of excellence, including VHIO, this Consortium will strive to address the deficit of integrative approaches that effectively combine different types of data from different sources as well as actively involve end-users that are not experts in bioinformatics in the design of the applications. www.medbioinformatics.eu.
Spurred by Horizon 2020’s European Union funding for Research and Innovation funding, MoTriColor (Molecularly guided Trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of Colorectal cancer), led by VHIO, is powered by a total of eight clinical research centers of excellence, spanning Spain, Italy, The Netherlands and Belgium, as well as a European organization in cancer research and a diagnostic/prognostic SME. Dedicated to conducting multi-center early phase clinical trials to establish the anti-tumor activity of novel experimental therapies for patients with metastatic or advanced colorectal cancer (CRCm), patients will be stratified based on their gene expression profiles according to recently established predictive signatures.
According to gene expression profiles, patients will then be matched to a particular clinical trial. This pioneering approach aims at identifying sensitivity of individual patients to the proposed experimental therapies towards ultimately developing more precise anti-cancer therapies for these patients. www.motricolor.eu
RATHER - Rational Therapy for Breast Cancer is funded by the European Commission's 7th Framework Programme of Research and Development. Representing an important step in delivering on precision oncology by developing tailored therapies using a rational approach, this project will focus on two specific difficult-to-treat subtypes of breast cancer. Involving the combined efforts of six research institutions and two biomedical companies this is a five-year project that commenced in January 2011. www.ratherproject.com.
Incorporating a network of 27 research entities spanning 10 countries, SPECTAcolor - Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, is an initiative within the framework of the research program of the EORTC, supported by Alliance Boots. Launched in 2013, this is the first prospective fully annotated tumor samples Biobank and Biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer. http://spectacolor.eortc.org.
WIN - Worldwide Innovative Networking in personalized cancer medicine, initiated by the Institut Gustave Roussy (France) and The University of Texas, MD Anderson Cancer Center (USA) is a non profit, non-governmental organization incorporating 22 cancer centers and industry partners from five continents to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics. Promoted within the scope of this Consortium, WINTHER (WINTherapeutics) is a unique academic and international clinical trial (launched in 2012), aimed at better predicting drug sensitivity and optimizing individualized therapeutic decisions with improved clinical outcome for patients. www.winconsortium.org.
The AstraZeneca/MedImmune and VIO´s Alliance agreement, announced in 2015, will stimulate advancements at preclinical, clinical and translational research levels across the AstraZeneca’s oncology portfolio. Combining VHIO´s strengths in promoting cancer discovery through the integration of translational science and clinical research with AstraZeneca´s promising early stage oncology pipeline, the alliance will initially focus on areas including DNA damage repair, drug resistance, new drug combinations and molecular profiles for patient selection. Bookmark and visit VHIO´s website for forthcoming updates: www.vhio.net.
The CIBOT Consorcio de Investigación Biomédica y Oncología Traslacional (Consortium for Biomedical and Translational Research in Oncology), is a scientific program established in collaboration with Novartis in 2013. This initiative defines and develops research aimed at: determining the etiopathogenic mechanisms of cancer as well as developing novel or more efficient diagnostic and therapeutic tools; investigating the therapeutic potential of new antineoplastic agents; and applying cutting-edge technologies and latest data to advance cancer research. Specific areas of interest include the effects of HER-2 amplification pattern and prior Herceptin/TDM-1 therapy on HER-2 expression, the therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway, and targeting wild type c-KIT combination with PI3K pathway inhibition in basal-like PDXs. www.novartis.com.
The OCTC - Oncology Clinical and Translational Consortium, a collaborative scientific research network comprised of six renowned comprehensive cancer centers, was launched by GSK in 2013. While GSK gains OCTC's expertise in preclinical, translational and clinical development of novel anticancer therapeutics, the participating centers will have access to studies with GSK's early stage oncology pipeline and opportunities to accelerate and advance the next generation of novel oncology therapeutics. www.gsk.com.